CFDE Data Portal | Search CAPN1-AS1

	Label	Description
	CAPN1-AS1 Gene (Entity type)	ENSG00000254614 - CAPN1 antisense RNA 1
	GSE252944 AKT inhibition 10 v 15 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE158632 3 V 5 OXYQUINOLINE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE144443 0 V 6 NICOTINAMIDE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE197555 0 V 3 TRAMETINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE205976 GSE205978 CEP83 knockout TIME 1 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE145195 PPP2R3B overexpression 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE77108 saha 0 v 9 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE120210 GSE120214 TBXT brachyury inhibition 4 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 7 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS

CAPN1-AS1

ENSG00000254614 - CAPN1 antisense RNA 1

GSE252944 AKT inhibition 10 v 15 human dn

A Gene Set from LINCS

GSE158632 3 V 5 OXYQUINOLINE HUMAN DN

A Gene Set from LINCS

GSE144443 0 V 6 NICOTINAMIDE MOUSE UP

A Gene Set from LINCS

GSE197555 0 V 3 TRAMETINIB HUMAN UP

A Gene Set from LINCS

GSE205976 GSE205978 CEP83 knockout TIME 1 v 4 human dn

A Gene Set from LINCS

GSE145195 PPP2R3B overexpression 0 v 1 human dn

A Gene Set from LINCS

GSE77108 saha 0 v 9 human up

A Gene Set from LINCS

GSE120210 GSE120214 TBXT brachyury inhibition 4 v 0 human dn

A Gene Set from LINCS

GSE195663 cisplatin 7 v 1 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.